NCT00871780已完成4 期
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 224
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Timed 100-meter Walk Test (T100T)
研究概览
简要总结
The primary objective of the study is to evaluate the evolution of walking capacity as measured by the timed 100-meter walk test (T100T), timed 25-foot walk test (T25FW), maximum walking distance (MWD), and Expanded Disability Status Scale (EDSS) during the first year of therapy with natalizumab. The secondary objectives of this study are as follows:
- To evaluate the correlation between the MWD and EDSS and both walking tests, the T100T and the T25FW at Baseline, at Week 24 and at Week 48 of therapy.
- To determine how well each of the walking tests, T100T or T25FW, predicts walking limitations in all participants and in the subgroups of participants stratified by baseline EDSS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must give written informed consent and provide all authorizations required by local law (for example, Protected Health Information [PHI])
- •Men or women between 18 and 60 years of age, inclusive
- •Must have Expanded Disability Status Scale (EDSS) less than or equal to 5.5 at baseline
- •Must be able to walk at least 100 m without assistive devices
- •Must be natalizumab-naïve
- •Must have a documented diagnosis of a relapsing remitting form of multiple sclerosis (MS0 as defined by the revised McDonald Committee criteria (Polman et al., 2005)
- •Must have had a recent (within 3 months from baseline) magnetic resonance imaging (MRI)
- •Must have had at least 1 relapse in the previous year and must satisfy the locally approved therapeutic indications for Tysabri. If Tysabri is not yet approved in a specific country, patients must fulfill the following criteria:
- •Patients with high disease activity despite treatment with a beta-interferon defined as patients who have failed to respond to a full and adequate course of a beta-interferon
- •Patients must have had at least 1 relapse in the previous year while on therapy, and have at least 9 T2 hyperintense lesions in cranial MRI or at least 1 gadolinium (Gd)-enhancing lesion
- •Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined as patients who have had 2 or more disabling relapses in one year and 1 or more Gd-enhancing lesions on brain MRI or significant increase in T2 lesions as compared to a previous MRI
- •Must be stable in disability for at least 30 days prior to enrollment to the study
- •Must be stable in symptomatic management of the disease, specifically spasticity, depression and fatigue for at least 30 days prior to enrollment to the study
- •Must be considered by the Investigator to be free of signs and symptoms suggestive of progressive multifocal leukoencephalopathy (PML) based on medical history, physical examination, or laboratory testing
- •Must be willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including interferon [IFN] and glatiramer acetate [GA]) while being treated with natalizumab during the study.
排除标准
- •Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of the Screening Visit:
- •Onset of a relapse within 50 days prior to first infusion
- •Considered by the Investigator to be immunocompromised, based on medical history, physical examination, or laboratory testing or due to prior immunosuppressive treatment
- •History of, or available abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric (including major depression), renal, and/or other major disease that would preclude the administration of a recombinant humanized antibody immunomodulating agent. The Investigator must re-review the subject's medical fitness for participation and consider any diseases that would preclude treatment
- •History of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible)
- •Known history of human immunodeficiency virus infection or hematological malignancy
- •History of organ transplantation (including anti-rejection therapy)
- •A clinically significant infectious illness (cellulitis, abscess, pneumonia, septicemia) within 30 days prior to the Screening Visit
- •Treatment with immunosuppressant medications (mitoxantrone, cyclophosphamide, cyclosporine, azathioprine, methotrexate) within 6 months prior to Screening
- •Female subjects who are not postmenopausal for at least 1 year, surgically sterile (does not include tubal ligation), or willing to practice effective contraception (as defined by the Investigator) during the study
- •Women who are breastfeeding, pregnant, or planning to become pregnant while on study
- •Current enrollment in any other study treatment or disease study
- •Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol
- •Subjects with walking impairment due to causes other than MS
- •Other unspecified reasons that, in the opinion of the Investigator and/or Biogen Idec, make the subject unsuitable for enrollment into this study
- •NOTE: Other eligibility criteria may apply.
研究组 & 干预措施
Natalizumab
Experimental
natalizumab 300 mg IV every 4 weeks for 48 weeks
干预措施: BG00002 (natalizumab) (Drug)
结局指标
主要结局
Change From Baseline in the Timed 100-meter Walk Test (T100T)
时间窗: Baseline, Week 24, Week 48
In the T100T, the participant is instructed to walk as fast as possible for a distance of 100 meters.
Change From Baseline in the Timed 25-foot Walk Test (T25FW)
时间窗: Baseline, Week 24, Week 48
In the T25FW, the participant is instructed to walk as fast as possible for a distance of 25 feet.
Change From Baseline in Maximum Walking Distance (MWD)
时间窗: Baseline, Week 24, Week 48
Change From Baseline in Expanded Disability Status Scale (EDSS)
时间窗: Baseline, Week 24, Week 48
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
次要结局
- Correlation Between the EDSS and MWD (Pearson Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the EDSS and MWD (Spearman Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the T100T and T25FW (Pearson Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the T100T and T25FW (Spearman Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the EDSS and T100T (Spearman Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the EDSS and T25FW (Pearson Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the EDSS and T25FW (Spearman Correlation Coefficient)(Baseline, Week 24, Week 48)
- Correlation Between the EDSS and T100T (Pearson Correlation Coefficient)(Baseline, Week 24, Week 48)
- Improvement in Timed 25FT Walk Speed and T100T Speed at Week 24 and 48(Baseline, Week 24, Week 48)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effect of Walking Exercise on Functional Capacity and Productivity in Patients After Coronary Artery Bypass GraftCoronary Artery BypassCardiac RehabilitationNCT06013605Indonesia University42
已完成
不适用
Post-Stroke Walking Speed and Community Ambulation Conversion StudyChronic StrokeNCT04121754MedRhythms, Inc.87
已完成
不适用
The influence of neurological and non-neurological factors on walking capacity of chronic spinal cord injury patient.CTRI/2021/09/036674Sancheti Institute College of PhysiotherapyPune30
已完成
不适用
An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)Multiple SclerosisNCT01535664Acorda Therapeutics20
已完成
不适用
Assessment of Walking-related Fatigability in Patients With Multiple Sclerosis.Multiple SclerosisNCT03860675Hasselt University85